Advances in companion diagnostics and non-invasive testing have ushered the next generation of personalized medicine. The genomic and proteomic signature of disease has a deterministic role in the clinical progression and treatment management. Tissue and its diseased signature is the gold standard of diagnosis but it may not always be accessible. Serum while readily accessible lacks the intact DNA material for genetic analysis. The ability to efficiently access diseased samples and their DNA and protein repertoire for real-time diagnosis is critical to the clinical outcome. This is the premise on which Wellconn Diagnostics is founded. - Wellconn Diagnostics
Business Sector: | Residential, Commercial |